title: High plasma proopiomelanocortin in aggressive adrenocorticotropin-secreting tumors.
abstract: A specific propiomelanocortin (POMC) immunoradiometric assay was developed using antibodies directed against ACTH and beta-endorphin (beta end). Partially purified standard POMC was prepared from the human small cell lung carcinoma cell line DMS-79 culture medium. Ten units (U) POMC had the same displacement ability as one pg beta end in a C-terminal beta end radioimmunoassay and thus were close if not equal to 10 pg POMC. This POMC assay was used to investigate patients with ACTH-dependent Cushing's syndrome. Plasma POMC was undetectable (< 60 U/mL) in 17 normal controls and in 4 patients with Addison's disease (concomitant ACTH plasma levels between 362 and 1058 pg/mL). Forty-two patients with Cushing's disease were studied, either before (n = 25) or after (n = 17) bilateral adrenalectomy: 7 patients with highly invasive macroadenomas had high POMC plasma levels, between 240 and 4200 U/ml (concomitant ACTH plasma levels between 77 and 5730 pg/mL); 35 patients, including one with an invasive macroadenoma, had undetectable POMC plasma levels (concomitant ACTH plasma levels between 31 and 2820 pg/mL). Among 20 patients with histologically proven ectopic ACTH syndrome, 16 had high POMC plasma levels, between 80 and 8000 U/mL (concomitant ACTH plasma levels between 45 and 9265 pg/mL); all those tumors were malignant, and the highest POMC/ACTH plasma levels ratios (taken as an index of altered POMC processing) were observed in the 3 patients with small cell carcinomas of the lung; in one of these patients, ACTH and POMC plasma levels both decreased during the course of chemotherapy, in parallel with the reduction of the tumoral mass. Four patients with ectopic ACTH syndrome had undetectable POMC plasma levels (concomitant ACTH plasma levels between 78 and 335 pg/mL): they were all typical bronchial carcinoids. These data show that high POMC plasma level is neither specific for nor constant in ectopic ACTH syndrome. Rather it should be considered as a marker of tumor aggressivity, in pituitary- and non-pituitary tumors. Its diagnostic help appears limited for the most frequent cause of occult ectopic ACTH syndrome, the typical bronchial carcinoids.
authors.affiliation: Groupe d'Etude en Physiopathologie Endocrinienne, INSERM CJF 9208, Université René Descartes, Paris, France.
authors.forename: M L
authors.initials: ML
authors.lastname: Raffin-Sanson
authors.forename: J F
authors.initials: JF
authors.lastname: Massias
authors.forename: C
authors.initials: C
authors.lastname: Dumont
authors.forename: M C
authors.initials: MC
authors.lastname: Raux-Demay
authors.forename: M F
authors.initials: MF
authors.lastname: Proeschel
authors.forename: J P
authors.initials: JP
authors.lastname: Luton
authors.forename: X
authors.initials: X
authors.lastname: Bertagna
mesh_terms: D000182:ACTH Syndrome, Ectopic / Q000097:blood*; D000224:Addison Disease / Q000097:blood; D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood*; D011333:Pro-Opiomelanocortin / Q000097:blood*; D011863:Radioimmunoassay
chemical_list: D011333:Pro-Opiomelanocortin; D000324:Adrenocorticotropic Hormone